A Prognosis and Predicting Genetic Study of Lung Cancer
NCT ID: NCT03234179
Last Updated: 2017-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
500 participants
OBSERVATIONAL
2017-08-01
2037-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Genetic factors that determine individual predisposition to lung cancer have been identified via genome-wide association studies. These known common loci, however, explain only a small fraction of the familial risk of lung cancer. The hypothesis of this study is that there are genetic factors that confer inherited susceptibility among patients with primary non-small-cell lung cancer (NSCLC).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Correlation Between Lung Cancer Susceptibility, Drug Response and Genetic Polymorphism
NCT01280448
The Use of Molecular Radiogenomics in Non-small Cell Lung Cancer
NCT05541744
Demographics of Lung Cancer in Females
NCT07122245
Machine Learning to Construct an Association Model for Lung Cancer and Environmental Hormone
NCT06259461
Genetic Epidemiology of Lung Cancer
NCT00341835
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
FAMILY_BASED
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The patient was diagnosed of primary non-small cell lung cancer at the age \< 45 years old.
Exclusion Criteria
2. Patients who are combined with other malignancy and ongoing chemotherapy / radiation therapy.
3. Patients combined with coagulopathy.
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Taiwan University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jin-Shing Chen, PhD
Role: STUDY_DIRECTOR
National Taiwan University Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201705110RIND
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.